Kristoffer Hellstrand

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5562565/publications.pdf

Version: 2024-02-01

67 papers	2,873 citations	136740 32 h-index	174990 52 g-index
68 all docs	68 docs citations	68 times ranked	2925 citing authors

#	Article	IF	Citations
1	Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood, 2006, 108, 88-96.	0.6	226
2	Randomized comparison of 12 or 24 weeks of peginterferon Î±-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology, 2008, 47, 1837-1845.	3.6	196
3	Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood, 2000, 96, 1961-1968.	0.6	148
4	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. PLoS ONE, 2011, 6, e17232.	1.1	131
5	Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2002, 20, 125-133.	0.8	130
6	A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis. Journal of Clinical Investigation, 2001, 108, 1221-1228.	3.9	102
7	Role of NOX2-Derived Reactive Oxygen Species in NK Cellâ€“Mediated Control of Murine Melanoma Metastasis. Cancer Immunology Research, 2017, 5, 804-811.	1.6	86
8	Histamine Protects T Cells and Natural Killer Cells Against Oxidative Stress. Journal of Interferon and Cytokine Research, 1999, 19, 1135-1144.	0.5	81
9	NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species. British Journal of Haematology, 2006, 132, 91-98.	1.2	80
10	Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis. Blood, 2012, 119, 5832-5837.	0.6	75
11	Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Blood Reviews, 2013, 27, 209-216.	2.8	71
12	Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immunology, Immunotherapy, 1994, 39, 416-419.	2.0	58
13	Histamine in cancer immunotherapy: A preclinical background. Seminars in Oncology, 2002, 29, 35-40.	0.8	58
14	Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade. Cancer Immunology, Immunotherapy, 2019, 68, 163-174.	2.0	58
15	Cutting Edge: Antioxidative Properties of Myeloid Dendritic Cells: Protection of T Cells and NK Cells from Oxygen Radical-Induced Inactivation and Apoptosis. Journal of Immunology, 2007, 179, 21-25.	0.4	56
16	Remission maintenance therapy with histamine and interleukinâ€2 in acute myelogenous leukaemia. British Journal of Haematology, 1996, 92, 620-626.	1.2	55
17	The CD16âˆ’/CD56bright Subset of NK Cells Is Resistant to Oxidant-Induced Cell Death. Journal of Immunology, 2007, 179, 781-785.	0.4	55
18	Oxygen Radicals Induce Poly(ADP-Ribose) Polymerase-Dependent Cell Death in Cytotoxic Lymphocytes. Journal of Immunology, 2006, 176, 7301-7307.	0.4	51

#	Article	IF	Citations
19	The HLA-B â”21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood, 2019, 133, 1479-1488.	0.6	50
20	NOX2 in autoimmunity, tumor growth and metastasis. Journal of Pathology, 2019, 247, 151-154.	2.1	50
21	TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses. Journal of Immunology, 2015, 195, 1121-1128.	0.4	48
22	Detection of Human Cytokine-Secreting Cells in Distinct Anatomical Compartments. Immunological Reviews, 1991, 119, 5-22.	2.8	45
23	Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 1473-1484.	2.0	45
24	Histamine: A Novel Approach to Cancer Immunotherapy. Cancer Investigation, 2000, 18, 347-355.	0.6	44
25	Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Expert Review of Hematology, 2010, 3, 381-391.	1.0	44
26	Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. Haematologica, 2012, 97, 1904-1908.	1.7	44
27	Synergistic Activation of Human Natural Killer Cell Cytotoxicity by Histamine and Interleukin-2. International Archives of Allergy and Immunology, 1990, 92, 379-389.	0.9	41
28	Histamine Promotes the Development of Monocyte-Derived Dendritic Cells and Reduces Tumor Growth by Targeting the Myeloid NADPH Oxidase. Journal of Immunology, 2015, 194, 5014-5021.	0.4	38
29	Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells. Oncotarget, 2016, 7, 32046-32053.	0.8	37
30	NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. Oncotarget, 2015, 6, 42569-42574.	0.8	35
31	Oxygen radical production in leukocytes and disease severity in multiple sclerosis. Journal of Neuroimmunology, 2009, 213, 131-134.	1.1	34
32	Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. OncoImmunology, 2016, 5, e1041701.	2.1	34
33	Impact of ADAR-induced editing of minor viral RNA populations on replication and transmission of SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	34
34	Histamine and Interleukin-2 in Acute Myelogenous Leukemia. Leukemia and Lymphoma, 1997, 27, 429-438.	0.6	33
35	Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3. PLoS ONE, 2012, 7, e29370.	1.1	32
36	Role of the ERK Pathway for Oxidant-Induced Parthanatos in Human Lymphocytes. PLoS ONE, 2014, 9, e89646.	1.1	31

#	Article	IF	Citations
37	Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells. Journal of Leukocyte Biology, 1994, 55, 392-397.	1.5	27
38	Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2. Frontiers in Oncology, 2018, 8, 218.	1.3	25
39	NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease. Oncogene, 2019, 38, 1534-1543.	2.6	25
40	NOX2-Derived Reactive Oxygen Species in Cancer. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-15.	1.9	25
41	Regulation of the Natural Killer Cell Response to Interferon-Î± by Biogenic Amines. Journal of Interferon Research, 1992, 12, 199-206.	1.2	24
42	Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). Clinical Cancer Research, 2005, 11, 290-7.	3.2	23
43	Activation of cytotoxic lymphocytes by interferon-Î±: role of oxygen radical-producing mononuclear phagocytes. Journal of Leukocyte Biology, 2004, 76, 1207-1213.	1.5	21
44	Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. Blood Advances, 2022, 6, 2723-2730.	2.5	19
45	Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus. Journal of Virology, 2018, 92, .	1.5	18
46	Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia. Journal of Leukocyte Biology, 2017, 102, 467-474.	1.5	17
47	Adjuvant histamine in cancer immunotherapy. Seminars in Cancer Biology, 2000, 10, 29-39.	4.3	16
48	Melanoma immunotherapy: a battle against radicals?. Trends in Immunology, 2003, 24, 232-233.	2.9	16
49	Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML. Leukemia and Lymphoma, 2019, 60, 2771-2778.	0.6	15
50	Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation. Haematologica, 2022, 107, 1479-1482.	1.7	15
51	Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis. Cancer Immunology, Immunotherapy, 2004, 53, 840-1.	2.0	14
52	Chronic myeloid leukemic cells trigger poly(ADP-ribose) polymerase-dependent inactivation and cell death in lymphocytes. Journal of Leukocyte Biology, 2013, 93, 155-160.	1.5	14
53	Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination. JHEP Reports, 2022, 4, 100496.	2.6	14
54	Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype. Human Vaccines and Immunotherapeutics, 2020, 16, 109-111.	1.4	13

#	Article	IF	Citations
55	Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. Oncotarget, 2016, 7, 7586-7596.	0.8	13
56	Role of NOX2 for leukaemic expansion in a murine model of BCRâ€ABL1⁺ leukaemia. British Journal of Haematology, 2018, 182, 290-294.	1.2	11
57	Impact of IL-1Î² and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance. OncoImmunology, 2021, 10, 1944538.	2.1	11
58	Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species. Cancer Immunology Research, 2020, 8, 1532-1541.	1.6	10
59	Low Incidence of Reinfection With Endemic Coronaviruses Diagnosed by Real-Time PCR. Journal of Infectious Diseases, 2021, 223, 2013-2014.	1.9	9
60	Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2â€“Specific T Cells in Whole Blood. Journal of Infectious Diseases, 2022, 226, 208-216.	1.9	9
61	Histamine, cimetidine and colorectal cancer. Nature Medicine, 1996, 2, 364-364.	15.2	8
62	Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia. Cancer Immunology Research, 2018, 6, 1110-1119.	1.6	8
63	Transient and durable T cell reactivity after COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	7
64	Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapseâ€preventive immunotherapy in acute myeloid leukaemia. British Journal of Haematology, 2020, 188, e49-e53.	1.2	4
65	Impact of CYBA genotypes on severity and progression of multiple sclerosis. European Journal of Neurology, 2022, 29, 1457-1464.	1.7	2
66	Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia. Frontiers in Immunology, 2021, 12, 796072.	2.2	2
67	Presence of interferon-Î» 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. Scandinavian Journal of Gastroenterology, 2021, 56, 849-854.	0.6	1